Serving Traumatic Injury Patients And Surgeons During Pandemic Panic

Rob Wright, chief editor of Life Science Leader, recently conducted a virtual roundtable with three CEOs of publicly traded biopharmaceutical companies (view full video here). Karen Zaderej, CEO, AxoGen (NASDAQ: AXGN), a company making products to remedy peripheral nerve damage, saw her company’s revenue drop dramatically as elective procedures declined by more than 70 percent in late-March and early April. But the company’s products are also used in severe trauma injuries. In this segment, Zaderey shares how AxoGen serves patients and surgeons while projecting employee health during COVID-19.